← Back to Screener
Revolution Medicines, Inc. Common Stock (RVMD)
Price$149.27
Favorite Metrics
Price vs S&P 500 (26W)215.00%
Price vs S&P 500 (4W)49.66%
Market Capitalization$30.23B
All Metrics
Book Value / Share (Quarterly)$8.28
P/TBV (Annual)9.77x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-4.64
Price vs S&P 500 (YTD)88.87%
Net Profit Margin (TTM)-2833.88%
EPS (TTM)$-4.80
10-Day Avg Trading Volume4.56M
EPS Excl Extra (TTM)$-4.80
EPS (Annual)$-5.95
ROI (Annual)-59.55%
Net Profit Margin (5Y Avg)-1090.94%
Cash / Share (Quarterly)$10.28
ROA (Last FY)-48.05%
EBITD / Share (TTM)$-5.00
ROE (5Y Avg)-37.42%
Operating Margin (TTM)-3145.03%
Cash Flow / Share (Annual)$-4.64
P/B Ratio18.53x
P/B Ratio (Quarterly)9.44x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)2602.32x
ROA (TTM)-39.14%
EPS Incl Extra (Annual)$-5.95
Current Ratio (Annual)7.14x
Quick Ratio (Quarterly)6.97x
3-Month Avg Trading Volume3.25M
52-Week Price Return318.26%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.00
P/S Ratio (Annual)2610.48x
Asset Turnover (Annual)0.01x
52-Week High$155.01
Operating Margin (5Y Avg)-1188.51%
EPS Excl Extra (Annual)$-5.95
CapEx CAGR (5Y)40.41%
Tangible BV CAGR (5Y)30.65%
26-Week Price Return218.99%
Quick Ratio (Annual)6.97x
13-Week Price Return30.19%
Total Debt / Equity (Annual)0.16x
Current Ratio (Quarterly)7.14x
Enterprise Value$30,114.068
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)3.04%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3798.71%
Cash / Share (Annual)$10.28
3-Month Return Std Dev94.28%
Net Income / Employee (TTM)$-1
ROE (Last FY)-69.35%
EPS Basic Excl Extra (Annual)$-5.95
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.16x
EPS Incl Extra (TTM)$-4.80
Receivables Turnover (Annual)0.00x
ROI (TTM)-46.96%
P/S Ratio (TTM)2612.29x
Pretax Margin (5Y Avg)-1099.19%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.00
Price vs S&P 500 (52W)288.43%
Year-to-Date Return91.51%
5-Day Price Return58.53%
EPS Normalized (Annual)$-5.95
ROA (5Y Avg)-29.73%
Net Profit Margin (Annual)-3768.28%
Month-to-Date Return56.85%
Cash Flow / Share (TTM)$-3.25
EBITD / Share (Annual)$-6.26
Operating Margin (Annual)-4207.12%
LT Debt / Equity (Annual)0.16x
ROI (5Y Avg)-35.46%
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-4.80
P/TBV (Quarterly)9.77x
P/B Ratio (Annual)9.44x
Pretax Margin (TTM)-2830.92%
Book Value / Share (Annual)$8.28
Price vs S&P 500 (13W)29.50%
Beta1.41x
Revenue / Share (TTM)$0.00
ROE (TTM)-54.06%
52-Week Low$34.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.37
4.37
4.37
4.37
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RVMDRevolution Medicines, Inc. Common Stock | 2612.29x | — | — | — | $149.27 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company leverages proprietary structure-based drug discovery capabilities to create small molecules that bind to unconventional RAS variant sites. Its pipeline centers on RAS(ON) Inhibitors designed for use as monotherapy or in combination with other therapeutic agents.